

Diabetes Priority Delivery Workstream Agreement and Terms of Reference December 2017

1. Purpose

1.1 NHS England and the Association of the British Pharmaceutical Industry (ABPI) will convene a Diabetes Priority Delivery Workstream to address the national priorities for diabetes outcomes set out by NHS England in December 2016, which are aimed at improving outcomes for people with both Type 1 and Type 2 diabetes and those at risk of developing Type 2 Diabetes, namely:

- 1.1.1 Improving the uptake of structured education for people with diabetes
- 1.1.2 Improving the achievement of NICE-recommended treatment targets
- 1.1.3 New or expanded multi-disciplinary foot care teams (MDFTs)
- 1.1.4 New or expanded diabetes inpatient specialist nursing services (DISNs)
- 1.1.5 Identification of patients at risk of developing Type 2 diabetes

2. Approach

2.1 The Priority delivery workstream will provide a joint forum for regular, ongoing interaction between industry and NHS stakeholders to support achievement of the outcome improvement goals set out in 1.1 above. The Joint Forum will meet at least two times per year. We anticipate that over time, this forum will enable identification of mutual areas of interest improve diabetes outcomes.

2.2 To facilitate such collaboration, and to provide an objective assessment regarding clinical appropriateness, patient safety and scalability, Academic Health Science Networks and other NHS organisations are invited to discuss proposed collaborations originating from industry with the NHS England National Clinical Directorate for Obesity and Diabetes.

2.3 ABPI will establish a **Conduit Process** for collaborative proposals to improve diabetes outcomes originating from NHS organisations in England. The process will ensure that these proposals are swiftly, fairly and transparently disseminated to member companies with an interest in diabetes in the form of 'Invitations to Respond'. This process will not impact upon the existing Contracts Finder process but will rather serve as a mechanism for NHS organisations to assess rapidly whether there is industry interest in developing collaborative initiatives at a formative stage.

3. Rationale for the Diabetes Priority Delivery Workstream

3.1 NHS England and ABPI acknowledge and fully support the wide range of legal and governance requirements that already exist to guide interaction between industry and the NHS. These include:

- 3.1.1 NHS Procurement Guide for Commissioners of NHS-funded Services
- 3.1.2 UK and EU Competition Law
- 3.1.3 NHS England Conflicts of Interest Guidance
- 3.1.4 ABPI Competition Law Guidance
- 3.1.5 PMCPA Code of Practice
- 3.1.6 ABPI / DH Guide to Joint Working
- 3.1.7 ABPI Disclosure UK Process

3.2 The joint forum created through the establishment of a Diabetes Priority Delivery Workstream will enable timely progression of innovative agreements that benefit patients in the form of improved outcomes, greater efficiencies and appropriate adoption of evidence-based innovation and to provide a clear process for NHS organisations and pharmaceutical companies seeking to develop innovative collaborations.

4. Principles

- 4.1 All parties seek to deliver measurable improvements in outcomes through effective, trusted partnerships, which will support the adoption of innovation and the most efficient use of public money.
- 4.2 Collaborations arising from this Diabetes Framework Agreement, whether national, regional or local, will be in accordance with the following principles:
 - 4.2.1 Rigour – partnership work will be evidence-based and underpinned with effective and transparent governance to ensure collaborations have a firm foundation.
 - 4.2.2 Ambition – a shared goal of transforming diabetes outcomes in England by delivering first class medicines optimisation, driving evidence-based innovation into practice and generating evidence of the impact of innovation on patient outcomes.
 - 4.2.3 Transparency – All proceedings undertaken under this Diabetes Framework Agreement, and the results of all initiatives and collaborations, will be published when complete, subject to respecting commercial in confidence information.
 - 4.2.4 Fairness – Initiatives undertaken under the Diabetes Framework Agreement will be conducted with equality of opportunity and access to all participants, companies and organisations.

5. Potential Areas for Collaboration

- 5.1 A number of potential areas for collaboration have been identified, which the Priority Delivery Workstream may wish to explore further:
 - 5.1.1 Patients' experience of their diabetes treatment and care;
 - 5.1.2 The development of a holistic approach to care for people with T2 diabetes with lifestyle and diet;
 - 5.1.3 Support for general practice to deliver improved patient outcomes.
 - 5.1.4 Medicines optimisation and the role that medicines play in improving diabetes outcomes□
 - 5.1.5 Healthcare professional education, training and competency.

- 5.1.6 Options for shifting the treatment paradigm to early intervention and optimising treatment to reduce the time between diabetes onset and establishment of good glycaemic control
- 5.1.7 Workforce roles and the use of PAMs in diabetes clinical pathways

6. Governance

- 6.1 Dr Partha Kar, Assistant Clinical Director, Obesity and Diabetes NHS England and Colette Goldrick, NHS Engagement Director ABPI, will jointly oversee the establishment of a Diabetes Priority Delivery Workstream.
- 6.2 Membership of the Workstream will include:
 - 6.2.1 Representatives from NHS England Diabetes Programme team;
 - 6.2.2 Academic Health Science Networks (which will all be invited to attend);
 - 6.2.3 Local NHS commissioning organisations; and
 - 6.2.4 Industry representatives.
- 6.3 The Workstream will work flexibly through face-to-face and virtual meetings to maintain momentum.

7. Confidentiality and information governance

- 7.1 In the course of operation of the **Portal Process** and the **Conduit Process**, information may be shared which is commercial in confidence. All members of the Diabetes Priority Delivery Workstream undertake to respect this and not to share beyond necessary parties. All parties acknowledge that antitrust regulations must be respected in relation to the sharing of information between commercial organisations and other industry parties.

Review period

Diabetes Framework Agreement to be reviewed annually.

Next review date December 2018

Signed on behalf of NHS England

Dr Partha Kar, Associate National Clinical Director for Diabetes, NHS England

Signed on behalf of ABPI

Colette Goldrick, NHS Engagement Director, ABPI